End Stage Renal Disease Market Segmentation:
- By Treatment Type
- Hemodialysis
- Peritoneal Dialysis
- Transplantation
- Others
- By Product & Services
- Equipment (Dialysis machines, water treatment, dialyzers)
- Consumables (Bloodlines, dialysate solutions)
- Services (In-center dialysis, home dialysis support)
- Software (EMR systems, telehealth)
- Others
- By Setting
- In-center
- Home-based
- Regions
- By End User
- Hospitals
- Dialysis Centers
- Home Care
- Others (clinics, ASCs)
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The ESRD market size was valued at USD 80.0 billion in 2023.
Rising prevalence of diabetes and hypertension, technological advancements in dialysis products, favorable reimbursement policies, emerging home-based dialysis trend.
High treatment costs, shortage of skilled nephrologists, complications and comorbidities associated with ESRD treatment, stringent regulatory approvals.
The hemodialysis segment leads the ESRD market.
Fresenius Medical Care, DaVita, Baxter, B.Braun, Nipro, Medtronic, Nikkiso, Asahi Kasei, Toray, NxStage Medical.
The ESRD market is projected to reach USD 120.3 billion by 2030, growing at a CAGR of 6% during 2023-2030.
The key drivers are rising ESRD prevalence, technology innovation in dialysis products, patient-centric approaches, partnerships between device makers and dialysis providers.